(Reuters) – Aptalis Pharma Inc, a specialty drugmaker owned by private equity firm TPG Capital LP, has appointed underwriters for an initial public offering after efforts to sell the company failed, people familiar with the matter said on Wednesday.
Goldman Sachs Group Inc (GS.N) and JPMorgan Chase & Co (JPM.N) will lead the offering, which might not happen until next year, the people said on condition of anonymity because the discussions are private.
Representatives for TPG, Aptalis, Goldman Sachs and JPMorgan did not immediately respond to requests for comment.
Bridgewater, N.J.-based Aptalis makes drugs to treat gastroenterology and cystic fibrosis. It had revenues of about $530 million for the nine months ending June 30, according to Moody’s Investors Service Inc.
Buyout firm TPG bought the drugmaker, formerly known as Axcan Pharma, for $1.3 billion in 2008 and merged it with Eurand Pharmaceuticals in 2011. The combined company was renamed Aptalis.
Looking to ride a wave of deal making in specialty pharma, TPG held unsuccessful discussions to sell Aptalis earlier this year with a number of companies, including Elan Corp (ELN.I), Forest Laboratories Inc (FRX.N) and Sun Pharmaceutical Industries Ltd (SUN.NS), people familiar with the matter told Reuters in August.
A sale failed to materialize not just because of TPG’s price expectations of between $3 billion and $4 billion, which buyers found expensive, but also because of the changed circumstances for some prospective buyers, the people said at that time.
Elan agreed in July to sell itself to U.S. drugmaker Perrigo Co (PRGO.N) for $8.6 billion, while Forest announced in May that its long-time chief executive would retire at the end of the year.
Last month, Aptalis arranged a loan with banks to refinance debt and pay a dividend to TPG. Following push back from the lenders, the loan was downsized to $1.25 billion from $1.4 billion, making the dividend $400 million instead of $550 million as originally planned, according to Thomson Reuters Loan Pricing Corp.
It is still possible that a sale of Aptalis occurs, even as the company heads towards a stock market flotation.
Neiman Marcus, another TPG portfolio company, registered for an IPO before it agreed to be sold to a private equity consortium for $6 billion last month.
TPG was an investor in upscale retailer Neiman Marcus along with fellow buyout firm Warburg Pincus LLC, which also sold another one of its portfolio companies this year after filing plans to take it public. That company, Bausch & Lomb Holdings Inc was taken over in August by Valeant Pharmaceuticals International (VRX.TO) for $8.7 billion.
By Olivia Oran, Soyoung Kim and Greg Roumeliotis, Reuters
(Reporting by Olivia Oran, Soyoung Kim and Greg Roumeliotis in New York. Editing by Andre Grenon)
Image credit: David Bonderman, founding partner of TPG Capital, takes part in a panel discussion at the Milken Institute Global Conference in Beverly Hills, California May 1, 2013. REUTERS/Gus Ruelas